Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: MSCLF )

0.3776 UNCHANGED
Streaming Delayed Price Updated: 11:35 AM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.3776
Today's Range 0.3776 - 0.3776
52wk Range 0.2205 - 0.5701
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
From Satellos Bioscience Inc.
Via Business Wire

Performance

YTD
+14.46%
+14.46%
1 Month
+18.00%
+18.00%
3 Month
-27.97%
-27.97%
6 Month
+7.85%
+7.85%
1 Year
-10.10%
-10.10%

More News

Read More
Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Present at Upcoming Virtual Investor Conferences in March and April
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024
From Satellos Bioscience Inc.
Via Business Wire
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Commence Trading on the Toronto Stock Exchange
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Present at the Piper Sandler 35th Annual Healthcare Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Present at the Stifel 2023 Healthcare Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos Bioscience Inc. Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer
Via Newsfile
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.